A phase I/II multi-center study of Troxatyl™ in patients with refractory chronic lymphocytic leukemia (CLL), lymphoma or multiple myeloma (MM).

被引：0
|
作者：
Giles, F
Belanger, R
Toor, A
McLaughlin, P
Fayad, L
Beran, M
Albitar, M
Vose, J
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Hop Maison Neuve Rosemont, Res Ctr, Montreal, PQ H1T 2M4, Canada
[3] Univ Arkansas Med Sci, Myeloma & Transplantat Ctr, Little Rock, AR 72205 USA
[4] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[5] Univ Nebraska, Med Ctr, Lincoln, NE 68583 USA
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4902
引用
收藏
页码：289B / 289B
页数：1
相关论文
共 50 条
  • [1] Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study
    Van Den Neste, Eric
    Cazin, Bruno
    Janssens, Ann
    Gonzalez-Barca, Eva
    Jose Terol, Maria
    Levy, Vincent
    Perez de Oteyza, Jaime
    Zachee, Pierre
    Saunders, Andrew
    de Frias, Merce
    Campas, Clara
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (03) : 581 - 591
  • [2] Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study
    Eric Van Den Neste
    Bruno Cazin
    Ann Janssens
    Eva González-Barca
    María José Terol
    Vincent Levy
    Jaime Pérez de Oteyza
    Pierre Zachee
    Andrew Saunders
    Mercè de Frias
    Clara Campàs
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 581 - 591
  • [3] A phase 1, multi-center, dose escalation study of atiprimod in patients with refractory or relapsed multiple myeloma (MM).
    Wang, M
    Talpaz, M
    Jagannath, S
    Chanan-Khan, AA
    Alexanian, R
    Weber, DM
    Gavino, M
    Estrov, Z
    Harris, PJ
    Picker, D
    Schlossman, RL
    Tassone, P
    Anderson, KC
    Munshi, NC
    BLOOD, 2005, 106 (11) : 36A - 37A
  • [4] Phase I/II study of rituxan in chronic lymphocytic leukemia (CLL).
    O'Brien, S
    Freireich, E
    Andreeff, M
    Lerner, S
    Keating, M
    BLOOD, 1998, 92 (10) : 105A - 105A
  • [5] Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi-center, single-arm, open-label, phase 2 study
    Xu, Wei
    Zhou, Keshu
    Wang, Tingyu
    Yang, Shenmiao
    Liu, Lihong
    Hu, Yu
    Zhang, Wei
    Ding, Kaiyang
    Zhou, Jianfeng
    Gao, Sujun
    Xu, Bing
    Zhu, Zunmin
    Liu, Ting
    Zhang, Huilai
    Hu, Jianda
    Ji, Chunyan
    Wang, Shunqing
    Xia, Zhongjun
    Wang, Xin
    Li, Yan
    Song, Yongping
    Ma, Shuo
    Tang, Xinran
    Zhang, Bin
    Li, Jianyong
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (04) : 571 - 579
  • [6] A phase I/II study of the SYK inhibitor entospletinib in combination with obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia (CLL)
    Kittai, Adam
    Hashiguchi, Taylor
    Thurlow, Bria
    Gokcora, Basak
    Stadnik, Andrzej
    MacKinnon, Renee
    Stephen, Monette
    Moore, Lacey
    Persky, Daniel
    Park, Byung
    Spurgeon, Stephen
    Danilov, Alexey
    LEUKEMIA & LYMPHOMA, 2020, 61 : 76 - 77
  • [7] Phase I study of ofatumumab (OFA) in Japanese patients (JPN pts) with relapsed of refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL)
    Terui, Y.
    Ogura, M.
    Tobinai, K.
    Hatake, K.
    Suzuki, T.
    Muruyama, D.
    Miyazato, A.
    Katsura, K.
    Hotta, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [8] Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group
    Bergmann, Manuela A.
    Goebeler, Maria E.
    Herold, Michael
    Emmerich, Bertold
    Wilhelm, Martin
    Ruelfs, Corinna
    Boening, Lothar
    Hallek, Michael J.
    HAEMATOLOGICA, 2005, 90 (10) : 1357 - 1364
  • [9] A Phase II Study of Intermittent Duvelisib Dosing in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
    Shouse, Geoffrey P.
    Chen, Lu
    Siddiqi, Tanya
    Muir, Alex
    Brown, Jennifer R.
    Spurgeon, Stephen E.
    Danilov, Alexey
    BLOOD, 2023, 142
  • [10] A Phase II study of intermittent duvelisib dosing in patients with chronic lymphocytic leukemia/ small lymphocytic lymphoma (CLL/SLL)
    Shouse, Geoffrey
    Chen, Lu
    Siddiqi, Tanya
    Muir, Alex
    Brown, Jennifer
    Spurgeon, Stephen
    Danilov, Alexey
    LEUKEMIA & LYMPHOMA, 2023, 64 : S105 - S106
12345